Stéphane Gobron

Translating science into innovation Investment | Project management | Business development | Technology transfer | Partnerships RNAi, medical device, diagnostics, immuno-oncology, PNS disorders, inflammatory diseases...

AlyZ Biociences provides operational support or consulting services including scientific writing, preclinical development plan, business plan, ...

Repurposing a drug for the treatment of chemotherapy-induced peripheral neuropathies (CIPN) to improve cancer patient survival and quality of life

Neuronax’s aim is to develop NX210 (subcommissural organ-spondin derived peptide), a first-in class candidate supporting neural repair, in order to treat traumatic (SCI) or severe degenerative disorders of the CNS and to contribute to improve neurological function and quality of life of patients.

Unique integrated public-private platform of discovery, preclinical and clinical services fully dedicated to R&D of products in pain's management. In 2014, Analgesia Partnership became the Analgesia Institute, the leading research and innovation center for pain in France.

Biopharmaceutical company developing candidate-drugs to treat traumatic or degenerative disorders of the central nervous system (CNS). Our lead candidate, NX210 (subcommissural organ-spondin derived peptide), is a first-in-class neuroprotective and neuro-regenerative peptide which was characterized as a promising disease-modifying candidate for the treatment of various CNS disorders, including but not limited to spinal cord injuries (SCI), traumatic brain injuries (TBI), stroke, Multiple Sclerosis, Alzheimer or Parkinson’s diseases, and a potential treatment of rare neurodevelopmental disorders as well. Orphan Drug Designation (EU/3/13/1206) was granted by the European Commission to NX210 peptide designed after subcommissural organ-spondin for the treatment of spinal cord injury. - Selected to attend the UbiStart Tour, organized by The Galien Foundation and UbiFrance (2014) - Laureates of "Tremplin-Entreprise", the contest organized by the Senate and ESSEC (2004) - Selected by "Tremplins de la Fondation Aventis" (2002) - Laureates of iLab, the national contest for deep tech innovative companies organized by the French Ministry of Higher Education, Research and Innovation (2002)

Biotech company focused on the development of molecular diagnostics and personalized medicine (genetic polymorphism analysis, SNP, pharmacogenomic, pharmacogenetic). The company was one of the winner of "Tremplins de la Fondation Rhône Poulenc" (1998) and obtained an INPI award (2000).

Development of a new method to detect unknown genetic polymorphisms (SNPs)

"Analyse moléculaire des sécrétions de l'organe sous-commissural: rôles potentiels de la SCO-spondine dans le développement du SNC / Molecular analysis of subcommissural organ secretions: potential roles of the SCO-spondin during the CNS development" / Keywords: Thrombospondin; CNS; spinal cord; development; Reissner's fiber

"Conservation entre espèces d'un gène codant pour une protéine spécifique du SNC et étude de son expression / Interspecies conservation of a gene coding for a CNS-specific protein and study of its expression" / Keywords: phylogenesis; chordates; vertebrates; CNS; Reissner's fiber; subcommissural organ